SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Homma H. [Diffuse panbronchiolitis.] Nihon Kyobu Shikkan Gakkai Zasshi 1975; 13: 38395 (in Japanese).
  • 2
    Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis. Naika 1969; 23: 44251 (in Japanese).
  • 3
    Izumi T, Doi O, Nobechi A et al. [Nation-wide Survey of Diffuse Panbronchiolitis (Author's Translation).] Annual Report on the study of interstitial lung disease in 1982. Grant-in Aid from the Ministry of Health and Welfare of Japan, Tokyo, Japan. 1983; 341 (in Japanese).
  • 4
    Homma H, Yamanaka A, Tanimoto S et al. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 1983; 83: 639.
  • 5
    Kudoh S, Uetake T, Hagiwara K et al. [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis.] Nihon Kyobu Shikkan Gakkai Zasshi 1987; 25: 63242 (in Japanese).
  • 6
    Homma H. Diffuse panbronchiolitis. Jpn J. Med. 1986; 25: 32934.
  • 7
    Odaka M, Saito N, Hosoda Y et al. [An Epidemiological Study of DPB in a Large Company (Author's Translation).] Annual Report on the study of interstitial lung disease in 1980. Grant-in Aid from the Ministry of Health and Welfare of Japan, Tokyo, Japan. 1981; 2528 (in Japanese).
  • 8
    Kim YW, Han SK, Shim YS et al. The first report of diffuse panbronchiolitis in Korea: five case reports. Intern. Med. 1992; 31: 695701.
  • 9
    Chu YC, Yeh SZ, Chen CL, Chen CY, Chang CY, Chiang CD. Diffuse panbronchiolitis: report of a case. J. Formos. Med. Assoc. 1992; 91: 91215.
  • 10
    Tredaniel J, Cazals-Hatem D, Zalcman G, D’Agay MF, Capron F. Diffuse panbronchiolitis: efficacy of low-dose erythromycin. Respir. Med. 1994; 88: 47980.
  • 11
    Homer RJ, Khoo L, Smith GJ. Diffuse panbronchiolitis in a Hispanic man with travel history to Japan. Chest 1995; 107: 11768.
  • 12
    Hu H, Liu Y, Cai Z, Chen L. A case of diffuse panbronchiolitis. Chin. Med. J. (Engl.) 1996; 109: 94952.
  • 13
    Zainudin BM, Roslina AM, Fadilah SA, Samad SA, Sufarlan AW, Isa MR. A report of the first three cases of diffuse panbronchiolitis in Malaysia. Med. J. Malaysia 1996; 51: 13640.
  • 14
    Wang H, Sun T, Miao J, Li Y. A definite case of diffuse panbronchiolitis diagnosed by open lung biopsy, Chin. Med. J. (Engl.) 1998; 111: 864.
  • 15
    Tsang KW, Ooi CG, Ip MS et al. Clinical profiles of Chinese patients with diffuse panbronchiolitis. Thorax 1998; 53: 27480.
  • 16
    Poh SC, Wang YT, Wang WY. Diffuse panbronchiolitis—a case report. Singapore Med. J. 2001; 42: 2714.
  • 17
    Randhawa P, Hoagland MH, Yousem SA. Diffuse panbronchiolitis in North America. Report of three cases and of the literature. Am. J. Surg. Pathol. 1991; 15: 437.
  • 18
    Poletti V, Patelli M, Poletti G, Bertanti T, Spiga L. Diffuse panbronchiolitis observed in an Italian male. Sarcoidosis 1992; 9: 679.
  • 19
    Fitzgerald JE, King TE Jr, Lynch DA, Tuder RM, Schwarz MI. Diffuse panbronchiolitis in the United States. Am. J. Respir. Crit. Care Med. 1996; 154: 497503.
  • 20
    Schulte W, Szrepka A, Bauer PC, Guzman J, Costabel U. [Diffuse panbronchiolitis. A rare differential diagnosis of chronic obstructive lung disease.] Dtsch. Med. Wochenschr. 1999; 124: 5848 (in German).
  • 21
    Chantarotorn S, Palwatwichai A, Vattanathum A, Tantamacharik D. Diffuse panbronchiolitis, the first case reports in Thailand. J. Med. Assoc. Thai. 1999; 82: 8338.
  • 22
    Gulhan M, Erturk A, Kurt B et al. Diffuse panbronchiolitis observed in a white man in Turkey. Sarcoidosis Vasc. Diffuse Lung Dis. 2000; 17: 2926.
  • 23
    Claxton S, Markos J. A case of diffuse panbronchiolitis. Aust. N. Z. J. Med. 2000; 30: 99100.
  • 24
    Martinez JA, Guimaraes SM, Ferreira RG, Pereira CA. Diffuse panbronchiolitis in Latin America. Am. J. Med. Sci. 2000; 319: 1835.
  • 25
    Fisher MS Jr, Rush WL, Rosado-de-Christenson ML et al. Diffuse panbronchiolitis: histologic diagnosis in unsuspected cases involving North American residents of Asian descent. Arch. Pathol. Lab. Med. 1998; 122: 15660.
  • 26
    Brugiere O, Milleron B, Antoine M, Carette MF, Philippe C, Mayaud C. Diffuse panbronchiolitis in an Asian immigrant. Thorax 1996; 51: 10657.
  • 27
    Chen Y, Kang J, Li S. Diffuse panbronchiolitis in China. Respirology 2005; 10: 705.
  • 28
    Sugiyama Y, Kudoh S, Maeda H, Suzuki H, Takaku F. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am. Rev. Respir. Dis. 1990; 141: 145962.
  • 29
    Keicho N, Tokunaga K, Nakata K et al. Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis. Am. J. Respir. Crit. Care Med. 1998; 158: 84650.
  • 30
    Park MH, Kim YW, Yoon HI et al. Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients. Am. J. Respir. Crit. Care Med. 1999; 159: 5269.
  • 31
    Keicho N, Ohashi J, Tamiya G et al. Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis. Am. J. Hum. Genet. 2000; 66: 5017.
  • 32
    Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994; 49: 5312.
  • 33
    Sugiyama Y. Diffuse panbronchiolitis. Clin. Chest Med. 1993; 14: 76572.
  • 34
    Akai S, Okayama H, Shimura S, Tanno Y, Sasaki H, Takishima T. Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan. Am. Rev. Respir. Dis. 1992; 146: 7813.
  • 35
    Ichikawa Y, Ninomiya H, Koga H et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am. Rev. Respir. Dis. 1992; 146: 196203.
  • 36
    Kadota J, Sakito O, Kohno S et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am. Rev. Respir. Dis 1993; 147: 1539.
  • 37
    Yoshimura K, Iizuka S, Anzai C et al. Diffuse panbronchiolitis is closely associated with mutations of the CFTR gene. Am. J. Respir. Crit. Care Med. 2000; 161 (Suppl.): A77.
  • 38
    Sugiyama Y, Kudoh S, Kitamura S. [A case of the bare lymphocyte syndrome with clinical manifestations of diffuse panbronchiolitis.] Nihon Kyobu Shikkan Gakkai Zasshi 1989; 27: 9803 (in Japanese).
  • 39
    Donato L, De La Salle H, Hanau D et al. Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. J. Pediatr. 1995; 127: 895900.
  • 40
    Teisserenc H, Schmitt W, Blake N et al. A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol. Lett. 1997; 57: 1837.
  • 41
    Furukawa H, Murata S, Yabe T et al. Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J. Clin. Invest. 1999; 103: 7558.
  • 42
    Raghavan M. Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. J. Clin. Invest. 1999; 103: 5956.
  • 43
    Azuma A, Keicho N, Furukawa H, Yabe T, Kudoh S. Prolonged survival of a bare lymphocyte syndrome type I patient with diffuse panbronchiolitis treated with erythromycin. Sarcoidosis Vasc. Diffuse Lung Dis. 2001; 18: 31213.
  • 44
    Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001; 11: 115666.
  • 45
    Maeda M, Saiki S, Yamanaka A. Serial section analysis of the lesions in diffuse panbronchiolitis. Acta Pathol. Jpn 1987; 37: 693704.
  • 46
    Kamio K, Matsushita I, Hijikata M et al. Promoter analysis and aberrant expression of MUC5B gene in diffuse panbronchiolitis. Am. J. Respir. Crit. Care Med. 2005; 171: 94957.
  • 47
    Iwata M, Colby TV, Kitaichi M. Diffuse panbronchiolitis: diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations. Hum. Pathol. 1994; 25: 35763.
  • 48
    Takizawa H, Tadokoro K, Miyoshi Y et al. [Serological characterization of cold agglutinin in patients with diffuse panbronchiolitis.] Nihon Kyobu Shikkan Gakkai Zasshi 1986; 24: 25763 (in Japanese).
  • 49
    Koyama H, Nishimura K, Mio T, Ikeda A, Sugiura N, Izumi T. Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis. Thorax 1994; 49: 5404.
  • 50
    Akira M, Kitatani F, Lee YS et al. Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology 1988; 168: 4338.
  • 51
    Nishimura K, Kitaichi M, Izumi T, Itoh H. Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings. Radiology 1992; 184: 77985.
  • 52
    Hansell DM. Small airways diseases: detection and insights with computed tomography. Eur. Respir. J. 2001; 17: 1294313.
  • 53
    Nakata K. [Revision of Clinical Guidelines for DPB (Author's Translation).] Annual Report on the study of diffuse lung disease in 1998. Grant-in Aid from the Ministry of Health and Welfare of Japan, Tokyo, Japan. 1999; 10911 (in Japanese).
  • 54
    Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. [The long-term chemotherapy with erythromycin in chronic lower respiratory tract infections—first report: comparison with amoxicillin.] Kansenshogaku Zasshi 1986; 60: 3744 (in Japanese).
  • 55
    Yamamoto M, Kondo A, Tamura M, Izumi T, Ina Y, Noda M. [Long-term therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis.] Nihon Kyobu Shikkan Gakkai Zasshi 1990; 28: 130513 (in Japanese).
  • 56
    Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58: 1459.
  • 57
    Fujii T, Kadota J, Kawakami K et al. Long-term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995; 50: 124652.
  • 58
    Yamada G, Igarashi T, Itoh E, Tanaka H, Sekine K, Abe S. Centrilobular nodules correlate with air trapping in diffuse panbronchiolitis during erythromycin therapy. Chest 2001; 120: 198202.
  • 59
    Ichikawa Y, Hotta M, Sumita S, Fujimoto K, Oizumi K. Reversible airway lesions in diffuse panbronchiolitis. Detection by high-resolution computed tomography. Chest 1995; 107: 1205.
  • 60
    Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow-up CT examination. Radiology 1993; 189: 55962.
  • 61
    Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. [The long-term chemotherapy with erythromycin in chronic lower respiratory tract infections—second report: including cases with Pseudomonas infections.] Kansenshogaku Zasshi 1986; 60: 4550 (in Japanese).
  • 62
    Yamamoto M. [A Double-blind Placebo-controlled Study on the Therapeutic Effect of Erythromycin on DPB (Author's Translation).] Annual Report on the study of diffuse lung disease in 1990. Grant-in Aid from the Ministry of Health and Welfare of Japan, Tokyo, Japan. 1991; 1820 (in Japanese).
  • 63
    Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med. 1998; 157: 182932.
  • 64
    Nakamura H, Fujishima S, Inoue T et al. Clinical and immuno-regulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur. Respir. J. 1999; 13: 13719.
  • 65
    Mikasa K, Sawaki M, Kita E et al. [Long-term chemotherapy using erythromycin (EM) for chronic lower airway infection: effectiveness of clarithromycin in EM ineffective cases—the fourth report.] Kansenshogaku Zasshi 1992; 66: 1097104 (in Japanese).
  • 66
    Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob. Agents Chemother. 1995; 39: 168890.
  • 67
    Nakata K, Taguchi Y, Kudoh S. [Therapeutic Guidelines for DPB (Author's Translation)]. Annual Report on the study of diffuse lung disease in 1999. Grant-in Aid from the Ministry of Health and Welfare of Japan, Tokyo, Japan. 2000;111 (in Japanese).
  • 68
    Cole PCA. ‘Vicious Circle’ hypothesis of the pathogenesis of bronchiectasis. Eur. J. Respir. Dis. 1986; 69 (Suppl.): 615.
  • 69
    Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airway in vitro. Am. Rev. Respir. Dis. 1990; 141: 728.
  • 70
    Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur. Respir. J. 1992; 5: 2348.
  • 71
    Mikami M. Clinical and pathophysiological significance of neutrophil elastase in sputum and the effect of erythromycin in chronic respiratory diseases. Nippon Kyoubu Shikkan Gakkai Zasshi (Jpn J. Thorac. Dis.) 1992; 29: 7283.
  • 72
    Ichikawa Y, Ninomiya H, Koga Tanaka M et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am. Rev. Respir. Dis. 1992; 146: 196203.
  • 73
    Oishi K, Sonoda F, Kobayashi S, Matsumoto K. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect. Immun. 1994; 62: 414552.
  • 74
    Takizawa H, Desaki M, Ohtoshi T et al. Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells; a potential mechanism of its anti-inflammatory action. Biochem. Biophys. Res. Commun. 1995; 210: 7816.
  • 75
    Takizawa H, Desaki M, Ohtoshi T et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am. J. Respir. Crit. Care Med. 1997; 156: 2668.
  • 76
    Desaki M, Takizawa H, Ohtoshi T et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem. Biophys. Res. Commun. 2000; 267: 1248.
  • 77
    Kawakami K, Kadota J, Iida K et al. Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells. Clin. Exp. Immunol. 1997; 107: 41016.
  • 78
    Keicho N, Kudoh S, Yotsumoto H, Akagawa KS. Anti-lymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J. Antibiot. 1993; 46: 140613.
  • 79
    Keicho N, Kudoh S, Yotsumoto H, Akagawa KS. Erythromycin promotes monocyte to macrophage differentiation. J. Antibiot. 1994; 47: 809.
  • 80
    Iino Y, Toriyama M, Kudo K, Natori Y, You A. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor-alpha production by human monocytes in vitro. Ann. Otol. Rhinol. Laryngol. Suppl. 1992; 157: 1620.
  • 81
    Kadota J, Mulkae H, Fujii T, Seki M, Tomono K, Kohno S. Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis. Chest 2004; 125: 123947.
  • 82
    Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63: 428.
  • 83
    Umeki S. Anti-inflammatory action of erythromycin. Its inhibitory effect on neutrophil NADPH oxidase activity. Chest 1993; 104: 11913.
  • 84
    Nelson S, Summer WR, Terry PB, Warr GA, Jakab GJ. Erythromycin induced suppression of pulmonary antibacterial defenses. Am. Rev. Respir. Dis. 1987; 136: 120712.
  • 85
    Hirata T, Matsunobe S, Matsui Y, Kado M, Mikiya K, Oshima S. Effect of erythromycin on the generation of neutrophil chemiluminescence in vitro. Nippon Kyoubu Shikkan Gakkai Zasshi (Jpn J. Thorac. Dis.) 1990; 28: 106671.
  • 86
    Oda H, Kadota JI, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994; 106: 111623.
  • 87
    Hojo M, Fujita I, Hamasaki Y, Miyazaki M, Miyazaki S. Erythromycin does not directly affect neutrophil functions. Chest 1994; 105: 5203.
  • 88
    Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006; 290: L7585.
  • 89
    Li YJ, Azuma A, Usuki J et al. EM703, a new derivative of erythromycin, improves bleomycin-induced pulmonary fibrosis in mice by inhibition of TGF-β signaling in fibroblasts. Respir. Res. 2006 (in press).
  • 90
    Tateda K, Hirakata Y, Furuya N, Ohno A, Yamaguchi K. Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1993; 37: 67580.
  • 91
    Nakata K, Totsu T, Tanaka N, Akashi T, Kanegasaki S. Inhibitory effects of macrolide antibiotics at low concentrations on verotoxin production by pathogenic E. coli O157. Jpn J. Antibiot. 1998; 51 (Suppl.): 14650.
  • 92
    Tateda K, Standiford TJ, Pechere JC, Yamaguchi K. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr. Pharm. Des. 2004; 10: 305565.
  • 93
    Sofer D, Gilboa-Garber N, Belz A, Garber NC. Sub-inhibitory erythromycin represses production of Pseudomonas aeruginosa lectins, autoinducer and virulence factors. Chemotherapy 1999; 45: 33541.
  • 94
    Molinari G, Guzman CA, Pesce A, Schito GC. Inhibition of Pseudomonas aeruginosa virulence factors by sub-inhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother. 1993; 31: 6818.
  • 95
    Sato K, Suga M, Nishimura J, Kushima Y, Muranaka H, Ando M. Pyocyanine synthesis by Pseudomonas aeruginosa in chronic airway infection and the effect of erythromycin on its biological activity. Jpn J. Antibiot. 1997; 50 (Suppl.): 8991.
  • 96
    Omura S, Tsuzuki K, Sunazuka T et al. Macrolides with gastrointestinal motor stimulating activity. J. Med. Chem. 1987; 30: 19413.
  • 97
    Kucers A, Crowe SM, Grayson ML, Hoy JF. The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs, 5th edn. Butterworth-Heinemann, Oxford, 1997; 61416.
  • 98
    Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N. Engl. J. Med. 2004; 351: 108996.
  • 99
    Azuma A, Kudoh S. Editorial: securing safety and efficacy of macrolide therapy for chronic small airway diseases. Intern. Med. 2005; 44: 1678.
  • 100
    Tsang KW, Ho PI, Chan KN et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur. Respir. J. 1999; 13: 3614.